Table 1.

Study features of the 12 eligible records.

Author (Year)	Country	Study type	Patients	Testing time	Group	Clinical outcome	Quality score
Asim M (2017)	USA	Retrospective	38	Pretherapy	≥5.5 vs. <5.5	PFS, OS	10
Jeyakumar G (2017)	USA	Retrospective	42	Pretherapy	≥3 vs. <3	PFS, OS	11
Lalani A (2018)	USA	Retrospective	142	Under therapy	deNLR vs. inNLR	PFS, OS	10
				Baseline	≥3.9 vs. <3.9	PFS, OS
Zahoor H (2018)	USA	Retrospective	90	Baseline	≥4.2 vs. <4.2	PFS	8
Rohit K (2018)	USA	Retrospective	65	Pretherapy	≥5 vs<5	OS	7
Suzuki K (2019)	Japan	Retrospective	65	Under therapy	deNLR vs. inNLR	PFS, OS	9
				Pretherapy	≥5 vs<5	PFS, OS
Ishihara H (2019)	Japan	Retrospective	58	Pretherapy	≥3 vs. <3	PFS, OS	8
Giorgi U (2019)	Italy	Prospective	196	Baseline	≥3 vs. <3	OS	9
Simonaggio A (2020)	France	Retrospective	86	Under therapy	deNLR vs. inNLR	PFS, OS	10
				Baseline	≥3 vs. <3	PFS, OS
Nishiyama N (2020)	Japan	Retrospective	52	Baseline	≥3 vs. <3	PFS, OS	8
Rebuzzi S (2020)	Italy	Retrospective	404	Baseline	≥3 vs. <3	PFS, OS	8
Arnab B (2020)	USA	Retrospective	37	Under therapy	deNLR vs. inNLR	PFS, OS	7

deNLR, decrease of NLR; inNLR, increase of NLR; OS, overall survival; PFS, progression-free survival.